Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study

• Autores principales: Mario Ouwens, PhD (Autor), Annie Darilay, PhD (Autor), Yiduo Zhang, PhD (Autor), Pralay Mukhopadhyay, PhD (Autor), Helen Mann, MSc (Autor), James Ryan, MSc (Autor), Phillip A. Dennis, MD (Autor)
• Formato: Libro
• Publicado: Elsevier, 2021-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

ABSTRACT: Background: Historically, the standard of care for patients with unresectable, Stage III non-small cell lung cancer had been concurrent chemoradiotherapy. However, outcomes had been poor, with approximately 15% to 32% of patients alive at 5 years. In the placebo-controlled Phase III A PACI...